Literature DB >> 23015663

Single nucleotide polymorphisms (SNPs) in non-small cell lung cancer (NSCLC) patients.

Rafael Rosell, Jia Wei.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23015663      PMCID： PMC3528379          DOI： 10.1634/theoncologist.2012-0205

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  11 in total

1.  BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

Authors:  Anthony C Faber; Ryan B Corcoran; Hiromichi Ebi; Lecia V Sequist; Belinda A Waltman; Euiheon Chung; Joao Incio; Subba R Digumarthy; Sarah F Pollack; Youngchul Song; Alona Muzikansky; Eugene Lifshits; Sylvie Roberge; Erik J Coffman; Cyril H Benes; Henry L Gómez; José Baselga; Carlos L Arteaga; Miguel N Rivera; Dora Dias-Santagata; Rakesh K Jain; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2011-07-22       Impact factor: 39.397

2.  In cancer drug resistance, germline matters too.

Authors:  Emily H Cheng; Charles L Sawyers
Journal:  Nat Med       Date:  2012-04-05       Impact factor: 53.440

3.  Toxicity in chemotherapy--when less is more.

Authors:  Alessandro Laviano; Filippo Rossi Fanelli
Journal:  N Engl J Med       Date:  2012-06-14       Impact factor: 91.245

4.  Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.

Authors:  Rebecca Suk; Sarada Gurubhagavatula; Sohee Park; Wei Zhou; Li Su; Thomas J Lynch; John C Wain; Donna Neuberg; Geoffrey Liu; David C Christiani
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

Review 5.  Platinum resistance related to a functional NER pathway.

Authors:  Rafael Rosell; Pedro Mendez; Dolores Isla; Miquel Taron
Journal:  J Thorac Oncol       Date:  2007-12       Impact factor: 15.609

6.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Authors:  King Pan Ng; Axel M Hillmer; Charles T H Chuah; Wen Chun Juan; Tun Kiat Ko; Audrey S M Teo; Pramila N Ariyaratne; Naoto Takahashi; Kenichi Sawada; Yao Fei; Sheila Soh; Wah Heng Lee; John W J Huang; John C Allen; Xing Yi Woo; Niranjan Nagarajan; Vikrant Kumar; Anbupalam Thalamuthu; Wan Ting Poh; Ai Leen Ang; Hae Tha Mya; Gee Fung How; Li Yi Yang; Liang Piu Koh; Balram Chowbay; Chia-Tien Chang; Veera S Nadarajan; Wee Joo Chng; Hein Than; Lay Cheng Lim; Yeow Tee Goh; Shenli Zhang; Dianne Poh; Patrick Tan; Ju-Ee Seet; Mei-Kim Ang; Noan-Minh Chau; Quan-Sing Ng; Daniel S W Tan; Manabu Soda; Kazutoshi Isobe; Markus M Nöthen; Tien Y Wong; Atif Shahab; Xiaoan Ruan; Valère Cacheux-Rataboul; Wing-Kin Sung; Eng Huat Tan; Yasushi Yatabe; Hiroyuki Mano; Ross A Soo; Tan Min Chin; Wan-Teck Lim; Yijun Ruan; S Tiong Ong
Journal:  Nat Med       Date:  2012-03-18       Impact factor: 53.440

7.  Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

Authors:  R de las Peñas; M Sanchez-Ronco; V Alberola; M Taron; C Camps; R Garcia-Carbonero; B Massuti; C Queralt; M Botia; R Garcia-Gomez; D Isla; M Cobo; M Santarpia; F Cecere; P Mendez; J J Sanchez; R Rosell
Journal:  Ann Oncol       Date:  2006-01-11       Impact factor: 32.976

8.  Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.

Authors:  Ji Qian; Hui-Qi Qu; Lixin Yang; Ming Yin; Qiming Wang; Shaohua Gu; Qihan Wu; Xueying Zhao; Wenting Wu; Junjie Wu; Xiaoming Tan; Wenqing Chen; Haijian Wang; Jiucun Wang; Weiwei Fan; Hongyan Chen; Baohui Han; Daru Lu; Qingyi Wei; Li Jin
Journal:  Oncologist       Date:  2012-07-27

9.  XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

Authors:  Sarada Gurubhagavatula; Geoffrey Liu; Sohee Park; Wei Zhou; Li Su; John C Wain; Thomas J Lynch; Donna S Neuberg; David C Christiani
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

10.  Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Authors:  Wei Zhou; Sarada Gurubhagavatula; Geoffrey Liu; Sohee Park; Donna S Neuberg; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531
View more
  4 in total

1.  CD40 -1C>T polymorphism and the risk of lung cancer in a Chinese population.

Authors:  Gang Zhou; Ying Wang; Ziyao Fang; Rongrong Liu; Anhui Wang; Feng Zhao; Lihua Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  Effect of XPC polymorphisms on the response to platinum-based chemotherapy: a meta-analysis.

Authors:  Chenyao Xie; Jing Zhao; Wenxi Hua; Pei Tan; Yudi Chen; Jingwen Rui; Xiaohan Sun; Jiaying Fan; Xiangyu Wei; Xiaojing Xu; Xiaoqin Yang
Journal:  Onco Targets Ther       Date:  2019-05-16       Impact factor: 4.147

Review 3.  Smartphone-Based Platforms for Clinical Detections in Lung-Cancer-Related Exhaled Breath Biomarkers: A Review.

Authors:  Qiwen Yu; Jing Chen; Wei Fu; Kanhar Ghulam Muhammad; Yi Li; Wenxin Liu; Linxin Xu; Hao Dong; Di Wang; Jun Liu; Yanli Lu; Xing Chen
Journal:  Biosensors (Basel)       Date:  2022-04-08

4.  Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer.

Authors:  Dongfang Tang; Yu Chen Zhao; Danwen Qian; Hongliang Liu; Sheng Luo; Edward F Patz; Patricia G Moorman; Li Su; Sipeng Shen; David C Christiani; Carolyn Glass; Wen Gao; Qingyi Wei
Journal:  Mol Carcinog       Date:  2019-11-12       Impact factor: 5.139
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.